204688-61-9

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-1-N-Boc-3-pyrrolidineacetic acid is used as an intermediate in the synthesis of pharmaceutical compounds for its ability to be selectively deprotected and further functionalized. The chiral nature of the (S)-enantiomer is particularly important in the development of enantiomerically pure drugs, as different enantiomers can exhibit different biological activities.
Used in Organic Chemistry Research:
In the field of organic chemistry research, (S)-1-N-Boc-3-pyrrolidineacetic acid serves as a model compound for studying the reactivity of protected amines and the stereochemistry of reactions involving chiral centers. Its use allows chemists to explore new synthetic methodologies and understand the influence of stereochemistry on reaction outcomes.
Used in the Production of Chiral Building Blocks:
(S)-1-N-Boc-3-pyrrolidineacetic acid is utilized as a chiral building block in the creation of complex organic molecules with specific biological activities. The Boc-protected pyrrolidine ring can be incorporated into a wide range of target molecules, including those with potential applications in medicine, agrochemicals, and other specialty chemicals.
Used in Analytical Chemistry:
(S)-1-N-Boc-3-pyrrolidineacetic acid can be employed as a chiral reference material in analytical chemistry for the development and validation of methods for enantiomeric separation and quantification. The distinct spatial configuration of the (S)-enantiomer makes it suitable for calibrating instruments and establishing the performance characteristics of chiral analytical techniques.

InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(15)12-5-4-8(7-12)6-9(13)14/h8H,4-7H2,1-3H3,(H,13,14)/t8-/m0/s1

Upstream product

• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1332331-37-9 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-(2-hydroxy-2-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-33-5 2-(2-aminoethyl)-4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-30-2 (4-[4-(1-benzofuran-5-yl)phenyl]-3-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)acetonitrile 
• 1332331-29-9 2-(4-[4-(1-benzofuran-5-yl)phenyl]-3-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)acetamide 
• 1332333-22-8 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-21-1 4-[4-(1-benzofuran-6-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-20-0 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[4-(1H-indol-4-yl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-19-7 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-(2-hydroxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-18-6 methyl (4-[4-(1-benzofuran-5-yl)phenyl]-3-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)acetate 
• 1332331-08-4 GSK 2194069 
• 1332331-17-5 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[⁽³⁵⁾-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-[2-(methyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332331-16-4 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-(1-methylethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332333-15-9 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[2-fluoro-4-(8-fluoro-2-naphthalenyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332333-14-8 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[2-fluoro-4-(6-fluoro-2-naphthalenyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 

Relevant academic research and scientific papers

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.